Resumen de SEOM clinical guideline for the management of malignant melanoma (2017)

Alfonso Berrocal Jaime, Ana Arance Fernández, V. E. Castellón Rubio, Luis de la Cruz-Merino, E. Espinosa Arranz, María González Cao, José Luis González Larriba, Iván Márquez Rodas, Ainara Soria, Salvador Martín Algarra

• All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams.